(R)-(-)-2-(苄氧基羰基)-1,2,3,4-四氢-3-异喹啉羧酸 | 146684-74-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 四氢异喹啉
• 中文名称: (R)-(-)-2-(苄氧基羰基)-1,2,3,4-四氢-3-异喹啉羧酸
• 中文别名: 苄氧羰基-D-1,2,3,4-四氢异喹啉-3-羧酸
• 英文名称: (R)-(+)-2-(benzyloxycarbonyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid
• 英文别名: (R)-(-)-2-(benzyloxycarbonyl)-1,2,3,4-tetrahydro-3-isoquinolinecarboxylic acid；Z-D-Tic-OH；(3R)-2-phenylmethoxycarbonyl-3,4-dihydro-1H-isoquinoline-3-carboxylic acid
• CAS: 146684-74-4
• 化学式: C₁₈H₁₇NO₄
• 分子量: 311.337
• InChiKey: YWVQGUBCAUFBCP-MRXNPFEDSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  23
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  66.8
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 海关编码：
  2933499090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: (3R)-2-Carbobenzoxy-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid
Synonyms: Z-D-Tic-oh

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: (3R)-2-Carbobenzoxy-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid
CAS number: 146684-74-4

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C18H17NO4
Molecular weight: 311.3

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  (R)-(-)-2-(苄氧基羰基)-1,2,3,4-四氢-3-异喹啉羧酸 在 四溴化碳 、 1-羟基苯并三唑一水物 、 三乙胺 、 N,N'-二环己基碳二亚胺 、 三苯基膦 作用下， 以 二氯甲烷 、 乙腈 为溶剂， 生成 (R)-(+)-N-[4-[4-(2-methoxyphenyl)piperazin-1-yl]butyl]-2-(benzyloxycarbonyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamide
  参考文献：
  名称：

  有效和高度选择性的D3受体配体的合成和药理评估：抑制可卡因的寻找行为和多巴胺D3 / D2受体的作用。

  摘要：

  描述了一系列与BP897（3）结构相关的新型芳烷基哌嗪的合成，药理学评估和构效关系（SAR）。在结合研究中，针对一组多巴胺，5-羟色胺和去甲肾上腺素受体亚型对新衍生物进行了测试。SAR研究主要集中于多巴胺D（3）受体，揭示了高受体亲和力和选择性所需的许多结构特征。探索了几种杂芳族系统的多巴胺受体亲和力，并结合了合成，生物学和分子模型，用于鉴定有效和选择性D（3）受体配体发展的新型结构。引入与二氯苯基哌嗪系统连接的吲哚环提供了迄今为止已知的两种最有效和选择性的配体（D（3）受体亲和力在皮摩尔范围内）。强大的D（3）受体配体的子集的内在药理学性质也通过[（35）S] -GTPgammaS结合测定进行了评估。动物研究的证据尤其突出了多巴胺能系统在环境刺激如何诱导药物寻求行为中的作用。因此，我们测试了两种新型D（3）受体部分激动剂和一种有效的D（3）选择性拮抗剂，在体内在长期禁欲后通过重新引入可卡

  DOI：

  10.1021/jm0211220

文献信息

• [EN] SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS AS FACTOR XIA INHIBITORS<br/>[FR] COMPOSÉS TÉTRAHYDROISOQUINOLINES SUBSTITUÉS EN TANT QU'INHIBITEURS DU FACTEUR XIA
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2013055984A1

  公开（公告）日：2013-04-18

  The present invention provides compounds of Formula (I): or stereoisomers, pharmaceutically acceptable salts thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of factor XIa and/or plasma kallikrein which may be used as medicaments.

  本发明提供了化合物的公式(I)：或其立体异构体，以及其药学上可接受的盐，其中所有变量如本文所定义。这些化合物是XIa因子和/或血浆激肽酶的抑制剂，可用作药物。
• INDOLIZINE COMPOUNDS, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
  申请人：LES LABORATOIRES SERVIER

  公开号：US20150051189A1

  公开（公告）日：2015-02-19

  Compounds of formula (I): wherein R a , R b , R c , R d , R 1 , R 2 , R 3 , R 4 , R 5 , X, Y and Het are as defined in the description. Medicinal products containing the same which are useful in treating pathologies involving a deficit in apoptosis, such as cancer, auto-immune diseases, and diseases of the immune system.

  式(I)的化合物： 其中R a ，R b ，R c ，R d ，R 1 ，R 2 ，R 3 ，R 4 ，R 5 ，X，Y和Het如描述中所定义。 含有相同化合物的药物，对于治疗涉及凋亡缺陷的病理，如癌症、自身免疫疾病和免疫系统疾病，具有益处。
• PHOSPHATE COMPOUNDS, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
  申请人：LES LABORATOIRES SERVIER

  公开号：US20150031648A1

  公开（公告）日：2015-01-29

  Compounds of formula (I): wherein X, Y, A 1 , A 2 , R a , R b , R c , R d , R 3 , R 4 , T and R 5 are as defined in the description. Medicinal products containing the same which are useful in treating pathologies involving a deficit in apoptosis, such as cancer, auto-immune diseases, and diseases of the immune system.

  式(I)的化合物：其中X、Y、A1、A2、Ra、Rb、Rc、Rd、R3、R4、T和R5的定义如描述中所示。包含这些化合物的药物制剂对于治疗涉及凋亡缺陷的病理，如癌症、自身免疫疾病和免疫系统疾病，具有益处。
• Privileged structure-guided synthesis of quinazoline derivatives as inhibitors of trypanothione reductase
  作者：Andrea Cavalli、Federica Lizzi、Salvatore Bongarzone、Reto Brun、R. Luise Krauth-Siegel、Maria Laura Bolognesi

  DOI：10.1016/j.bmcl.2009.04.060

  日期：2009.6

  designed as inhibitors of the parasite specific enzyme trypanothione reductase (TR), and their biological activities were evaluated. Some of our compounds inhibited TR, showed selectivity for TR over human glutathione reductase, and inhibited parasite growth in vitro. We propose that the quinazoline framework is a privileged structure that can be purposely modified to design novel TR inhibitors. Furthermore

  设计了新型喹唑啉类化合物作为寄生虫特异性酶锥虫硫醚还原酶（TR）的抑制剂，并对其生物学活性进行了评估。我们的某些化合物抑制TR，对TR的选择性高于人类谷胱甘肽还原酶，并在体外抑制了寄生虫的生长。我们建议喹唑啉框架是一种特权结构，可以有意地对其进行修饰以设计新型TR抑制剂。此外，特权图案的使用可能会作为一种抗寄生虫潜在候选人的创新方法而出现。
• Phosphate compounds, a process for their preparation and pharmaceutical compositions containing them
  申请人：LES LABORATOIRES SERVIER

  公开号：US09115159B2

  公开（公告）日：2015-08-25

  Compounds of formula (I): wherein X, Y, A1, A2, Ra, Rb, Rc, Rd, R3, R4, T and R5 are as defined in the description. Medicinal products containing the same which are useful in treating pathologies involving a deficit in apoptosis, such as cancer, auto-immune diseases, and diseases of the immune system.

  化合物式(I)：其中X，Y，A1，A2，Ra，Rb，Rc，Rd，R3，R4，T和R5的定义如说明书所述。含有该化合物的药物制剂可用于治疗涉及凋亡缺陷的病理，如癌症、自身免疫疾病和免疫系统疾病。